Author:
Ochi Nobuaki,Miyake Noriko,Takeyama Masami,Yamane Hiromichi,Fukazawa Takuya,Nagasaki Yasunari,Kawahara Tatsuyuki,Ichiyama Naruhiko,Kosaka Youko,Mimura Ayaka,Nakanishi Hidekazu,Hiraki Akio,Kiura Katsuyuki,Takigawa Nagio
Funder
Kawasaki Medical School
Boehringer Ingelheim Vetmedica Japan Co Ltd
Nihon Kayaku Kabushiki Kaisha
Reference39 articles.
1. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US;Ganti;JAMA Oncol.,2021
2. Cancer Information Service, National Cancer Center, Japan;Cancer Statistics,2022
3. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations;Tan;J. Clin. Oncol.,2022
4. Gefitinib or Erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: Individual patient data meta-analysis of overall survival;Lee;J. Natl. Cancer Inst.,2017
5. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N. Engl. J. Med.,2018